Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Safety and Antifungal Activity of Recombinant Interferon-Gamma 1b (rIFN-Gamma 1b) Given With Standard Therapy in Patients With Cryptococcal Meningitis
This study has been completed.
Study NCT00012467 Information provided by InterMune
First Received: March 9, 2001 Last Updated: May 29, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Meningitis, Cryptococcal
HIV Infections
Additional conditions recognized in this trial
Acquired Immunodeficiency Syndrome
Infection
Meningitis
More general conditions related to this trial
Central Nervous System Diseases
Central Nervous System Fungal Infections
Central Nervous System Infections
Cryptococcosis
Immune System Diseases
Immunologic Deficiency Syndromes
Lentivirus Infections
Meningitis, Fungal
Mycoses
Nervous System Diseases
Retroviridae Infections
RNA Virus Infections
Sexually Transmitted Diseases
Sexually Transmitted Diseases, Viral
Slow Virus Diseases
Virus Diseases
Interventions listed in this trial
Itraconazole
Flucytosine
Fluconazole
Amphotericin B
Interferon gamma-1b
Additional drug interventions recognized in this trial
Abelcet
Antifungal Agents
Hydroxyitraconazole
Interferon Type II
Interferon-gamma, Recombinant
Interferons
Liposomal amphotericin B
More general drug interventions related to this trial
Amebicides
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antifungal
Antimetabolites
Antineoplastic Agents
Antiparasitic Agents
Antiprotozoal Agents
Antiviral Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
InterMune
Back to top of Main Content
